Effective proliferation of human regulatory T cells requires a strong costimulatory CD28 signal that cannot be substituted by IL-2

被引:41
作者
Hombach, Andreas A. [1 ]
Kofler, David [1 ]
Hombach, Anja [1 ]
Rappl, Gunter [1 ]
Abken, Hinrich [1 ]
机构
[1] Univ Cologne, Lab Tumorgenet, Innere Med Klin 1, Zentrum Mol Med Koln, Cologne, Germany
关键词
D O I
10.4049/jimmunol.179.11.7924
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The strength of immune repression by regulatory T (Treg) cells is thought to depend on the efficiency of Treg cell activation. The stimuli and their individual strength required to activate resting human Treg cells, however, have so far not been elucidated in detail. We reveal here that induction of proliferation of human CD4(+)C25(+) Treg cells requires an extraordinary strong CD28 costimulatory signal in addition to TCR/CD3 engagement. CD28 costimulation, noteworthy, cannot be substituted by IL-2 to induce proliferation of Treg cells, which is in contrast to CD4(+)CD25(-) T cells. IL-2, in contrast, prevents spontaneous apoptosis of Treg cells, but does not initiate their amplification. IL-2 and CD28 costimulation clearly exhibit disparate effects on Treg cells which are in contrast to those on CD4(+)CD25(-) T cells. Moreover, the prerequisites for Treg cell proliferation differ strikingly from those for effector T cells, implying a balanced orchestration in initiating and limiting a T cell immune response. In addition, data are of relevance for the design of therapeutic strategies involving IL-2 administration and CD28 costimulation.
引用
收藏
页码:7924 / 7931
页数:8
相关论文
共 29 条
[1]   Tuning tumor-specific T-cell activation: a matter of costimulation? [J].
Abken, H ;
Hombach, A ;
Heuser, C ;
Kronfeld, K ;
Seliger, B .
TRENDS IN IMMUNOLOGY, 2002, 23 (05) :240-245
[2]   IL-2 administration increases CD4+CD25hi Foxp3+ regulatory T cells in cancer patients [J].
Ahmadzadeh, M ;
Rosenberg, ST .
BLOOD, 2006, 107 (06) :2409-2414
[3]   Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production [J].
Allan, Sarah E. ;
Crome, Sarah Q. ;
Crellin, Natasha K. ;
Passerini, Laura ;
Steiner, Theodore S. ;
Bacchetta, Rosa ;
Roncarolo, Maria G. ;
Levings, Megan K. .
INTERNATIONAL IMMUNOLOGY, 2007, 19 (04) :345-354
[4]   CD4+CD25high regulatory cells in human peripheral blood [J].
Baecher-Allan, C ;
Brown, JA ;
Freeman, GJ ;
Hafler, DA .
JOURNAL OF IMMUNOLOGY, 2001, 167 (03) :1245-1253
[5]   Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis [J].
Beyersdorf, N ;
Gaupp, S ;
Balbach, K ;
Schmidt, J ;
Toyka, KV ;
Lin, CH ;
Hanke, T ;
Hünig, T ;
Kerkau, T ;
Gold, R .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (03) :445-455
[6]   In vivo alloreactive potential of ex vivo expanded primary T lymphocytes [J].
Contassot, E ;
Murphy, W ;
Angonin, R ;
Pavy, JJ ;
Bittencourt, MC ;
Robinet, R ;
Reynolds, CW ;
Cahn, JY ;
Herve, P ;
Tiberghien, P .
TRANSPLANTATION, 1998, 65 (10) :1365-1370
[7]   Ex vivo isolation and characterization of CD4+CD25+ T cells with regulatory properties from human blood [J].
Dieckmann, D ;
Plottner, H ;
Berchtold, S ;
Berger, T ;
Schuler, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (11) :1303-1310
[8]   A function for interleukin 2 in Foxp3-expressing regulatory T cells [J].
Fontenot, JD ;
Rasmussen, JP ;
Gavin, MA ;
Rudensky, AY .
NATURE IMMUNOLOGY, 2005, 6 (11) :1142-1151
[9]  
Gavin MA, 2006, P NATL ACAD SCI USA, V103, P6659, DOI 10.1073/pnas.0509484103
[10]  
JENKINS MK, 1990, J IMMUNOL, V144, P16